C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza
{"title":"462 在ENGOT-EN6-NSGO/GOG-3031/RUBY试验中,与单纯化疗相比,多司他单抗联合化疗治疗原发性晚期/复发性子宫内膜癌患者的无进展生存期2-无进展生存期1","authors":"C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza","doi":"10.1136/ijgc-2024-esgo.25","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"62 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza\",\"doi\":\"10.1136/ijgc-2024-esgo.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"62 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial